All sponsors

InxMed (Shanghai) Co., Ltd.

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-13
ACTIVE TRIALS8
PHASE 3 / 2-31
RECRUITING2
READOUTS ≤12 MONTHS1
READOUT SLIPPED >6 MO57%

Delay Index: of 7 active trials registered more than a year ago, 4 have moved their primary completion (readout) date by more than 6 months since first registration (median +9.9 months). See all sponsors →

Open InxMed (Shanghai) Co., Ltd. on the live radar map →
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
IN10018
NCT05994131
P1/2Active, not recruitingNSCLC1102025-09-20 (-10 mo)
IN10018
NCT05827796
P1/2Active, not recruitingPancreatic Cancer702025-10-11 (-2 mo)
IN10018
NCT06030258
P1/2Active, not recruitingSmall Cell Lung Cancer Extensive Stage1202025-11-20 (+10 mo)
IN10018 in combination with PLD
NCT05551507
P1/2Active, not recruitingPlatinum-resistant Ovarian Cancer1502026-05-11 (+23 mo)
IN10018
NCT06014528
P2Active, not recruitingOvarian Cancer Recurrent1682027-03-24 (+28 mo)
D1553
NCT06166836
P1/2Active, not recruitingSolid Tumor1402027-12-31 (+24 mo)
IN10018 in combination with D-1553
NCT07174908
P3RecruitingNon-Small Cell Lung Cancer4002028-09
IN10018 in combination with RNK08954
NCT07441174
P1/2RecruitingSolid Tumor Cancer; PDAC922031-02-28